References

• Auclair, D., Miller, D., Yatsula, V., Pickett, W., Carter, C., Chang, Y., et al. (2007). Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia (Vol. 21).
• Bamborough, P., Angell, R. M., Bhamra, I., Brown, D., Bull, J., Christopher, J. A., et al. (2007). N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: Indazoles as phenol isosteres with improved pharmacokinetics. Bioorganic & Medicinal Chemistry Letters (Vol. 17).
• Barrios Sosa, A. C., Boschelli, D. H., Ye, F., Golas, J. M., & Boschelli, F. (2004). Synthesis and inhibition of Src kinase activity by 7-ethenyl and 7-ethynyl-4-anilino-3-quinolinecarbonitriles. Bioorganic & Medicinal Chemistry Letters (Vol. 14).
• Coward, P., Conn, M., Tang, J., Xiong, F., Menjares, A., & Reagan, J. D. (2009). Application of an allosteric model to describe the interactions among retinol binding protein 4, transthyretin, and small molecule retinol binding protein 4 ligands. Anal Biochem (Vol. 384).
• Day, J. E. H., Sharp, S. Y., Rowlands, M. G., Aherne, W., Workman, P., & Moody, C. J. (2010). Targeting the Hsp90 chaperone: synthesis of novel resorcylic acid macrolactone inhibitors of Hsp90. Chemistry (Vol. 16).
• Drake, K. A., Zhang, J. – H., Harrison, R. K., & McGeehan, G. M. (2002). Development of a homogeneous, fluorescence resonance energy transfer-based in vitro recruitment assay for peroxisome proliferator-activated receptor delta via selection of active LXXLL coactivator peptides. Anal Biochem (Vol. 304).
• Kane, C. D., Stevens, K. A., Fischer, J. E., Haghpassand, M., Royer, L. J., Aldinger, C., et al. (2009). Molecular Characterization of Novel and Selective Peroxisome Proliferator-Activated Receptor {alpha} Agonists with Robust Hypolipidemic Activity in Vivo. Mol Pharmacol (Vol. 75).
• Lee, G., Elwood, F., McNally, J., Weiszmann, J., Lindstrom, M., Amaral, K., et al. (2002). T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem (Vol. 277).
• Li, Y., Wang, Z., Furukawa, N., Escaron, P., Weiszmann, J., Lee, G., et al. (2008). T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties. J Biol Chem (Vol. 283).
• Liu, J., Knappenberger, K. S., Kack, H., Andersson, G., Nilsson, E., Dartsch, C., et al. (2003). A Homogeneous in Vitro Functional Assay for Estrogen Receptors: Coactivator Recruitment. Mol Endocrinol (Vol. 17).
• Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., et al. (1999). Identification of a Nuclear Receptor for Bile Acids. Science (Vol. 284).
• Najima, Y., Yahagi, N., Takeuchi, Y., Matsuzaka, T., Sekiya, M., Nakagawa, Y., et al. (2005). High Mobility Group Protein-B1 Interacts with Sterol Regulatory Element-binding Proteins to Enhance Their DNA Binding. J Biol Chem (Vol. 280).
• Ohshima, A., Takamatsu, Y., & Saitoh, H. (2010). Efficient Selection of Cell Clones with Higher Productivity in the Production of Recombinant Human Monoclonal Antibodies. JAACT: Basic and Applied Aspects.
• Porter, J., Payne, A., Whitcombe, I., de Candole, B., Ford, D., Garlish, R., et al. (2009). Atropisomeric small molecule Bcl-2 ligands: Determination of bioactive conformation. Bioorganic & Medicinal Chemistry Letters (Vol. 19).
• So, C. H., Verma, V., Alijaniaram, M., Cheng, R., Rashid, A. J., O’Dowd, B. F., et al. (2009). Calcium Signaling by Dopamine D5 Receptor and D5-D2 Receptor Hetero-Oligomers Occurs by a Mechanism Distinct from That for Dopamine D1-D2 Receptor Hetero-Oligomers. Mol Pharmacol (Vol. 75).
• Tremblay, G. B., Kunath, T., Bergeron, D., Lapointe, L., Champigny, C., Bader, J. A., et al. (2001). Diethylstilbestrol regulates trophoblast stem cell differentiation as a ligand of orphan nuclear receptor ERR beta. Genes & Development (Vol. 15).
• Wickens, P., Kluender, H., Dixon, J., Brennan, C., Achebe, F., Bacchiocchi, A., et al. (2007). SAR of a novel ‘Anthranilamide Like’ series of VEGFR-2, multi protein kinase inhibitors for the treatment of cancer. Bioorganic & Medicinal Chemistry Letters (Vol. 17).
• Wood, E. R., Shewchuk, L., Hassel, A., Nichols, J., Truesdale, A. T., Smith, D., et al. (2009). Discovery of an inhibitor of insulin-like growth factor 1 receptor activation: Implications for cellular potency and selectivity over insulin receptor. Biochemical Pharmacology.
• Zhang, W. X., Wang, R., Wisniewski, D., Marcy, A. I., LoGrasso, P., Lisnock, J. – M., et al. (2005). Time-resolved Forster resonance energy transfer assays for the binding of nucleotide and protein substrates to p38alpha protein kinase. Anal Biochem (Vol. 343).
• Zhou, V., Han, S., Brinker, A., Klock, H., Caldwell, J., & Gu, X. -ju. (2004). A time-resolved fluorescence resonance energy transfer-based HTS assay and a surface plasmon resonance-based binding assay for heat shock protein 90 inhibitors. Anal Biochem (Vol. 331).
• Ziegler, D. S., Wright, R. D., Kesari, S., Lemieux, M. E., Tran, M. A., Jain, M., et al. (2008). Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. J Clinical Investigation (Vol. 118).